Some companies are born out of necessity, or opportunity. See an underserved market, build a better mousetrap, etc. For Gilead Sciences (GILD) founder Michael Riordan, dengue fever was the mother of invention. Bitten by a mosquito and hospitalized for three weeks, nauseated, fatigued, and otherwise compromised, Riordan lamented the lack of drugs available for treating viruses such as that then inhabiting his bloodstream. So he decided to formulate one.

27 years later, Gilead is one of the quiet success stories of both medicine and Wall Street. The company now produces 16 drugs, which treat everything from cystic fibrosis (Cayston) to angina (Renexa.) Another couple of dozen treatments are on their way to market. The remainder of Gilead’s current roster combats pulmonary hypertension (Fiolan, Letairis), serious eye inflammations (Vistide, Macugen), fungal infections (AmBisone), and hepatitis B (Hepsera.) There’s also Lexiscan, a nuclear medicine treatment that opens blood vessels for examination. Gilead isn’t combating fibromyalgia and restless legs syndrome, but rather some of the most nefarious and insidious ailments around. (For related reading, see: What Are The Best Bets In Biotech?)

At The Forefront of Fighting HIV/AIDS

That leaves what are far and away Gilead’s two biggest moneymakers, HIV/AIDS drugs and flu treatments. The company produces no fewer than seven pharmaceuticals to fight HIV/AIDS, with prices ranging from $18 to $40 to $90 a pill. (There are multiple reasons why Gilead develops multiple HIV/AIDS drugs, contraindications being a major one.) When Michael Riordan was initially struck with a relatively tame viral infection, no one could predict that more impactful ones would become part of the landscape in the upcoming years. HIV/AIDS has since killed and rendered ill thousands of people, providing an opportunity for companies such as Gilead to capitalize upon. (If that sounds distasteful, consider the alternative – Gilead developing nothing.) (For related reading, see: Why There's Far More To Pfizer Than Viagra.)

Stacking The Deck

With the progress from drug development to public availability being famously sluggish in the United States, Riordan preemptively lured some of the most powerful people in Washington to serve as Gilead board members and executives. They include former cabinet secretaries Carla Hills, George Shultz and Donald Rumsfeld. For whatever reasons, Gilead drugs make it to market relatively quickly. Which dovetails with the story of what is perhaps Gilead’s most famous creation, Tamiflu. (For more, see: The Cost of Getting The Flu.)

In the mid-to-late 2000s, the fear of fatal contamination by “bird flu” swept much of the developed world. Even though bird flu cases were almost entirely restricted to rural parts of Southeast Asia, and numbered only in the dozens. Nevertheless, even with no reported cases in the United States, Tamiflu’s previous manufacturer sold tens of millions of doses to governments and non-governmental organizations. The United States Department of Health and Human Services authorized the purchase of $200 million worth of Tamiflu, in anticipation of an epidemic that still has yet to materialize. At the time, Gilead’s former chairman served as Secretary of Defense, sitting a chair or two away from the HHS Secretary.

Big R&D Spend

HIV/AIDS drugs are notoriously difficult to develop, and thus expensive. Which makes sense from an Economics 101 perspective too – create a product with enormous utility (saving the infected from what was formerly regarded as a death sentence), and a small but enthusiastic market (the vast majority of people don’t have HIV/AIDS), and said product won’t be cheap. (For related reading, see: Pharmaceutical Phenoms: America's Best-Selling Medicines.)

Gilead’s latest and potentially most profitable creation, Sovaldi, treats hepatitis C. Well, that’s an understatement. Sovaldi cures nine out of 10 patients, far more than any of the drug’s predecessors. Not only that, Sovaldi is a pill. (Previous hepatitis C treatments required the patient to administer a syringe.) Developing cirrhosis isn’t something you’d hope for, and Sovaldi provides a considerably more pleasant alternative. Even at $1,000 a pill.

That wasn’t a typo. And considering that a round of Sovaldi treatment consists of 84 pills, some insurance companies balk at covering it. Sovaldi’s sticker price might be shocking – as are those of other life-sustaining drugs – but you get what you pay for (freedom from future liver transplants). Still, lawmakers and bureaucrats in some current national governments, including that of the United States, decry Gilead for charging so much, even labeling its price “unsustainable.” The unintended consequences of this are clear. If Gilead anticipates that one day the price of Sovaldi will be set below the market clearing price by legislation (as has already happened in the United Kingdom, India and Egypt), the reasonable course of action is to charge as high a price as possible now. Furthermore, what distinguishes Sovaldi from other expensive drugs is that its customer base is relatively large. A dose of elaprase costs three times as much as a dose of Sovaldi, but the former treats a disease that an estimated 2,000 people worldwide suffer from. Tens of millions have hepatitis C. The result is that Sovaldi has generated $6 billion for Gilead so far, which represents what’s typically almost half a year’s revenue for the company. (For related reading, see: How Johnson & Johnson Became A Household Name.)

The Bottom Line

Many giant corporations’ contributions to society are tough to discern, or even justify. Some Wall Street titans offer financial liquidity, while there are others that offer rich tobacco satisfaction in smokable form. Fortunately, that still leaves plenty of room for a company whose objective, modus operandi, and mission are to save lives and ease discomfort around the world. (For more, see: Evaluating Pharmaceutical Companies.)

Related Articles
  1. Stock Analysis

    Healthcare M&A and Prescription Drug Prices

    Learn how mergers among health care insurance companies and drug companies could lead to increased premiums for consumers and lower drug costs.
  2. Investing Basics

    From Startup To Blue Chip: The Success Story Of Gilead Sciences Inc.

    Learn how Gilead Sciences went from a startup to one of the more successful pharmaceutical companies in the industry, and learn about its major drugs.
  3. Chart Advisor

    Gilead Sciences Inc

    For today's chart we've chosen to take a look at Gilead Sciences Inc. (Nasdaq:GILD) because it recently tested the strength of an influential level of resistance. As you can see from the chart ...
  4. Mutual Funds & ETFs

    ETF Analysis: BioShares Biotechnology Products

    Learn more about the BioShares Biotechnology Products fund, an exchange-traded fund that is focused on producers of FDA-approved drugs.
  5. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  6. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  7. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
  8. Professionals

    How to Help Clients Spooked by Volatility

    Volatility spooks investors leading them to confuse it with risk. Here are ways to help guide your clients through times of volatility in the market.
  9. Professionals

    Boomers’ 401(k)s are Way Out of Whack: What to Do?

    Many baby boomers have been investing heavily in equities in their 401(k)s. Now may be the time to rebalance to avoid huge losses if the market tanks.
  10. Professionals

    How to Advise Clients on Company Stock in 401(k)s

    Holding company stock in a 401(k) has its risks. Here's how advisors can help clients avoid them.
  1. Securities-Based Lending

    The practice of making loans using securities as collateral. ...
  2. Orphan Drug

    A drug or biological product that treats a rare condition or ...
  3. Food And Drug Administration - ...

    A government agency established in 1906 with the passage of the ...
  1. How does the role of Medicare/Medicaid affect the drugs sector in the U.S.?

    Medicare and Medicaid have enormous influence on the pharmaceutical, or drugs, sector in the United States. For instance, ... Read Full Answer >>
  2. What factors make the drug sector good for value investing?

    The drugs sector is a good choice for value investing because it always has demand and a competitive moat. This simplifies ... Read Full Answer >>
  3. What annual return could an investor expect on average from the drug sector?

    The drugs sector consists of a diverse group of companies of different sizes in terms of market cap, revenues, profitability ... Read Full Answer >>
  4. What are the primary factors that drive share prices in the drugs sector?

    The primary factors that drive share prices in the drugs sector are mergers and acquisitions activity, spending on health ... Read Full Answer >>
  5. How does the profit margin compare for a generic drug versus a brand name drug?

    Profit margins are higher for generic drugs compared to brand-name drugs. However, total profits on brand-name drugs are ... Read Full Answer >>
  6. What level of return on equity is average for a company in the drugs sector?

    The drugs sector provides a variety of investing opportunities ranging from major drug manufacturing companies to generic ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!